Nutritional assessment of patients with non-small cell lung cancer treated with osimertinib. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is a leading cause of morbidity and mortality worldwide. Between 35% and 65% of NSCLC patients experience nutritional problems or malnutrition, which significantly affects their prognosis and quality of life. This study aims to describe the nutritional status and body composition of NSCLC patients treated with osimertinib, an oral tyrosine kinase inhibitor, while also assessing the prevalence of sarcopenia, presarcopenia, and dynapenia. Additionally, we explore the relationship between dose-limiting toxicities (DLTs) and nutritional status, as well as the impact of nutritional status on quality of life using the EQ-5D scale.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Gender
Timeframe: Day 0, During the consultation
Age
Timeframe: Day 0, During the consultation
Stage of NSCLC
Timeframe: Day 0, During the consultation
Start date of Osimertinib treatment
Timeframe: Day 0, During the consultation
Initial and current osimertinib dose
Timeframe: Day 0, During the consultation
Total duration of osimertinib treatment
Timeframe: Day 0, During the consultation
Dose-limiting toxicities (DLTs)
Timeframe: Day 0, During the consultation
Body weight
Timeframe: Day 0, During the consultation
Height
Timeframe: Day 0, During the consultation
Calf circumference
Timeframe: Day 0, During the consultation
Body mass index (BMI)
Timeframe: Day 0, During the consultation
Usual body weight
Timeframe: Day 0, During the consultation
Weight loss during treatment
Timeframe: Day 0, During the consultation
Food intake recall
Timeframe: Day 0, During the consultation
Fat mass (FM) by bioimpedance
Timeframe: Day 0, During the consultation
Lean body mass (LBM) by bioimpedance
Timeframe: Day 0, During the consultation
Lean body mass index (LBMI)
Timeframe: Day 0, During the consultation
Muscle functionality
Timeframe: Day 0, During the consultation